arrow
T

Timothy Voorhees

The Ohio State University
H指数:15
被引数:889

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

滤泡性淋巴瘤中,嵌合抗原受体T细胞疗法后双特异性抗体疗法的真实世界结局

2026-06-180
OAAI
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers

纳武利尤单抗联合AVD方案作为经典霍奇金淋巴瘤患者的一线治疗方案:一项来自20家美国中心的真实世界分析

2026-03-310
OAAI
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

美国多中心回顾性研究:浆细胞样淋巴瘤的预后与治疗

2026-03-230
OAAI
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate

非霍奇金淋巴瘤患者接受大剂量甲氨蝶呤治疗时与末相甲氨蝶呤清除率相关的临床特征

2026-02-010
PRE
Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapy

孤立性口腔CD30+/CD4+ CAR+ T细胞淋巴瘤在放疗后的长期缓解

2025-09-020
OAAI
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study

年龄对边缘区淋巴瘤生物学特征、临床表现和预后的影响:多中心队列研究的结果

2025-04-220
OAAI
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma

新诊断的原发性弥漫性大B细胞淋巴瘤患者中,循环淋巴瘤细胞在诊断时对预后的影响

2025-01-050
OA
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma

与新生侵袭性大b细胞淋巴瘤相比,CD19 CAR T在转化的惰性淋巴瘤中的结果

2024-12-230
OAAI
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

评估商业用Axicabtagene Ciloleucel(axi-cel)和Tisagenlecleucel(tisa-cel)治疗复发或难治性(R/R)滤泡性淋巴瘤(FL)的结局和毒性的研究:来自10家美国学术中心的真实世界证据(RWE)

BLOOD
IF23.1
2024-11-050
PRE
A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

一项Tazemetostat联合简化利妥昔单抗/苯达莫司汀方案治疗一线高肿瘤负荷滤泡性淋巴瘤的I/II期研究:一项Big Ten癌症研究联盟研究

BLOOD
IF23.1
2024-11-050
PRE
MANTLE CELL, FOLLICULAR, WALDENSTROM'S, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

套细胞型、滤泡型、Waldenström's以及其他惰性B细胞淋巴瘤:临床与流行病学

BLOOD
IF23.1
2024-11-050
PRE
Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
2024-06-131
OAAI